Recombinant alpha interferon in metastatic renal cell carcinoma : a cooperative phase II study
A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%),...
Gespeichert in:
| Veröffentlicht in: | Urology (Ridgewood, N.J.) N.J.), 1991-07, Vol.38 (1), p.60-63 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 63 |
|---|---|
| container_issue | 1 |
| container_start_page | 60 |
| container_title | Urology (Ridgewood, N.J.) |
| container_volume | 38 |
| creator | BONO, A. V REALI, L COPPI, F FRANCH, L BENVENUTI, C RIGATTI, P GIBBA, A COSCIANI-CUNICO, S BRAUSI, M VICINI, D PAVONE-MACALUSO, M ANSELMO, G |
| description | A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent. |
| doi_str_mv | 10.1016/0090-4295(91)80016-Z |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_1866861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1866861</sourcerecordid><originalsourceid>FETCH-LOGICAL-p167t-ed6e72962ce05408b0d9943a0a9cb114980170178ea51a4b9561a22b957327593</originalsourceid><addsrcrecordid>eNo9j81LAzEQxYMotVb_A4UcPOhhNcluvryV4kehIIhePFhms1Nc2c0uSSr0vzdgKQzzHvN-PBhCLjm744yre8YsKyph5Y3lt4blU_F5RKZcCl1Ya-UxmR6QU3IW4w9jTCmlJ2TCjVJG8Sn5ekM39HXrwScK3fgNtPUJwwbD4LOlPSaICVLraEAPHXXY5QXBtX7ogT5QoG4YRgyZ-UWaGyLS5ZLGtG125-RkA13Ei73OyMfT4_vipVi9Pi8X81UxcqVTgY1CLawSDpmsmKlZY21VAgPras4raxjXeQyC5FDVVioOQmTVpdDSljNy9d87busem_UY2h7Cbr3_M-fX-xyig24TwLs2HjApjCqtLv8ASDthkA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Recombinant alpha interferon in metastatic renal cell carcinoma : a cooperative phase II study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>BONO, A. V ; REALI, L ; COPPI, F ; FRANCH, L ; BENVENUTI, C ; RIGATTI, P ; GIBBA, A ; COSCIANI-CUNICO, S ; BRAUSI, M ; VICINI, D ; PAVONE-MACALUSO, M ; ANSELMO, G</creator><creatorcontrib>BONO, A. V ; REALI, L ; COPPI, F ; FRANCH, L ; BENVENUTI, C ; RIGATTI, P ; GIBBA, A ; COSCIANI-CUNICO, S ; BRAUSI, M ; VICINI, D ; PAVONE-MACALUSO, M ; ANSELMO, G</creatorcontrib><description>A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/0090-4295(91)80016-Z</identifier><identifier>PMID: 1866861</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Science</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Carcinoma, Renal Cell - secondary ; Carcinoma, Renal Cell - therapy ; Drug Evaluation ; Female ; Follow-Up Studies ; Humans ; Immunotherapy ; Interferon Type I - adverse effects ; Interferon Type I - therapeutic use ; Kidney Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Recombinant Proteins ; Remission Induction</subject><ispartof>Urology (Ridgewood, N.J.), 1991-07, Vol.38 (1), p.60-63</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5286397$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1866861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BONO, A. V</creatorcontrib><creatorcontrib>REALI, L</creatorcontrib><creatorcontrib>COPPI, F</creatorcontrib><creatorcontrib>FRANCH, L</creatorcontrib><creatorcontrib>BENVENUTI, C</creatorcontrib><creatorcontrib>RIGATTI, P</creatorcontrib><creatorcontrib>GIBBA, A</creatorcontrib><creatorcontrib>COSCIANI-CUNICO, S</creatorcontrib><creatorcontrib>BRAUSI, M</creatorcontrib><creatorcontrib>VICINI, D</creatorcontrib><creatorcontrib>PAVONE-MACALUSO, M</creatorcontrib><creatorcontrib>ANSELMO, G</creatorcontrib><title>Recombinant alpha interferon in metastatic renal cell carcinoma : a cooperative phase II study</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon Type I - adverse effects</subject><subject>Interferon Type I - therapeutic use</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Recombinant Proteins</subject><subject>Remission Induction</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j81LAzEQxYMotVb_A4UcPOhhNcluvryV4kehIIhePFhms1Nc2c0uSSr0vzdgKQzzHvN-PBhCLjm744yre8YsKyph5Y3lt4blU_F5RKZcCl1Ya-UxmR6QU3IW4w9jTCmlJ2TCjVJG8Sn5ekM39HXrwScK3fgNtPUJwwbD4LOlPSaICVLraEAPHXXY5QXBtX7ogT5QoG4YRgyZ-UWaGyLS5ZLGtG125-RkA13Ei73OyMfT4_vipVi9Pi8X81UxcqVTgY1CLawSDpmsmKlZY21VAgPras4raxjXeQyC5FDVVioOQmTVpdDSljNy9d87busem_UY2h7Cbr3_M-fX-xyig24TwLs2HjApjCqtLv8ASDthkA</recordid><startdate>19910701</startdate><enddate>19910701</enddate><creator>BONO, A. V</creator><creator>REALI, L</creator><creator>COPPI, F</creator><creator>FRANCH, L</creator><creator>BENVENUTI, C</creator><creator>RIGATTI, P</creator><creator>GIBBA, A</creator><creator>COSCIANI-CUNICO, S</creator><creator>BRAUSI, M</creator><creator>VICINI, D</creator><creator>PAVONE-MACALUSO, M</creator><creator>ANSELMO, G</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19910701</creationdate><title>Recombinant alpha interferon in metastatic renal cell carcinoma : a cooperative phase II study</title><author>BONO, A. V ; REALI, L ; COPPI, F ; FRANCH, L ; BENVENUTI, C ; RIGATTI, P ; GIBBA, A ; COSCIANI-CUNICO, S ; BRAUSI, M ; VICINI, D ; PAVONE-MACALUSO, M ; ANSELMO, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p167t-ed6e72962ce05408b0d9943a0a9cb114980170178ea51a4b9561a22b957327593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon Type I - adverse effects</topic><topic>Interferon Type I - therapeutic use</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Recombinant Proteins</topic><topic>Remission Induction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BONO, A. V</creatorcontrib><creatorcontrib>REALI, L</creatorcontrib><creatorcontrib>COPPI, F</creatorcontrib><creatorcontrib>FRANCH, L</creatorcontrib><creatorcontrib>BENVENUTI, C</creatorcontrib><creatorcontrib>RIGATTI, P</creatorcontrib><creatorcontrib>GIBBA, A</creatorcontrib><creatorcontrib>COSCIANI-CUNICO, S</creatorcontrib><creatorcontrib>BRAUSI, M</creatorcontrib><creatorcontrib>VICINI, D</creatorcontrib><creatorcontrib>PAVONE-MACALUSO, M</creatorcontrib><creatorcontrib>ANSELMO, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BONO, A. V</au><au>REALI, L</au><au>COPPI, F</au><au>FRANCH, L</au><au>BENVENUTI, C</au><au>RIGATTI, P</au><au>GIBBA, A</au><au>COSCIANI-CUNICO, S</au><au>BRAUSI, M</au><au>VICINI, D</au><au>PAVONE-MACALUSO, M</au><au>ANSELMO, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant alpha interferon in metastatic renal cell carcinoma : a cooperative phase II study</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>1991-07-01</date><risdate>1991</risdate><volume>38</volume><issue>1</issue><spage>60</spage><epage>63</epage><pages>60-63</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent.</abstract><cop>New York, NY</cop><pub>Elsevier Science</pub><pmid>1866861</pmid><doi>10.1016/0090-4295(91)80016-Z</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-4295 |
| ispartof | Urology (Ridgewood, N.J.), 1991-07, Vol.38 (1), p.60-63 |
| issn | 0090-4295 1527-9995 |
| language | eng |
| recordid | cdi_pubmed_primary_1866861 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - therapy Drug Evaluation Female Follow-Up Studies Humans Immunotherapy Interferon Type I - adverse effects Interferon Type I - therapeutic use Kidney Neoplasms - pathology Male Medical sciences Middle Aged Pharmacology. Drug treatments Recombinant Proteins Remission Induction |
| title | Recombinant alpha interferon in metastatic renal cell carcinoma : a cooperative phase II study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T05%3A48%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20alpha%20interferon%20in%20metastatic%20renal%20cell%20carcinoma%20:%20a%20cooperative%20phase%20II%20study&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=BONO,%20A.%20V&rft.date=1991-07-01&rft.volume=38&rft.issue=1&rft.spage=60&rft.epage=63&rft.pages=60-63&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/0090-4295(91)80016-Z&rft_dat=%3Cpubmed_pasca%3E1866861%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1866861&rfr_iscdi=true |